Abstract: The invention provides polypeptides (e.g., antibodies) and fusion proteins that target a epitope in the receptor binding domain (RBD) of the spike (S) glycoprotein of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The polypeptides and fusion proteins can be used to treat and prevent MERS-CoV infection in mammals.
Type:
Grant
Filed:
October 16, 2014
Date of Patent:
September 24, 2019
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, Veritech Limited
Inventors:
Dimiter S. Dimitrov, Tianlei Ying, Tina W. Ju, Kwok Yung Yuen
© 2026 Justia
